<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-14T15:38:43Z</responseDate>
  <request identifier="oai:figshare.com:article/34026790" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34026790</identifier>
        <datestamp>2026-09-29T17:37:52Z</datestamp>
        <setSpec>category_7</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_19</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_122</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Primary outcome: Overall survival.&lt;/p&gt;</dc:title>
          <dc:creator>Po-Huang Chen (8374326)</dc:creator>
          <dc:creator>Ming-Shen Dai (835570)</dc:creator>
          <dc:creator>Mao-Hsuan Huang (17475456)</dc:creator>
          <dc:creator>Hsin-Yu Chen (2165956)</dc:creator>
          <dc:creator>Li-Ting Kao (409065)</dc:creator>
          <dc:creator>Tina Yi-Jin Hsieh (22887737)</dc:creator>
          <dc:creator>Hong-Jie Jhou (9376258)</dc:creator>
          <dc:creator>Cho-Hao Lee (4114723)</dc:creator>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Pharmacology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Mental Health</dc:subject>
          <dc:subject>showed null associations</dc:subject>
          <dc:subject>related adverse events</dc:subject>
          <dc:subject>propensity score matching</dc:subject>
          <dc:subject>prior 365 days</dc:subject>
          <dc:subject>preceding 90 days</dc:subject>
          <dc:subject>level pattern matched</dc:subject>
          <dc:subject>groups may differ</dc:subject>
          <dc:subject>everyday functional ability</dc:subject>
          <dc:subject>enhancing antitumor immunity</dc:subject>
          <dc:subject>cd8 +&amp;# 8201</dc:subject>
          <dc:subject>cancer genome atlas</dc:subject>
          <dc:subject>20 cancer types</dc:subject>
          <dc:subject>first ici administration</dc:subject>
          <dc:subject>008 ), driven</dc:subject>
          <dc:subject>cannot localize slc6a4</dc:subject>
          <dc:subject>272 tumor samples</dc:subject>
          <dc:subject>year overall survival</dc:subject>
          <dc:subject>target trial emulation</dc:subject>
          <dc:subject>bzd prescription overlapping</dc:subject>
          <dc:subject>&gt;- value 2</dc:subject>
          <dc:subject>134 matched patients</dc:subject>
          <dc:subject>slc6a4 expression related</dc:subject>
          <dc:subject>immune checkpoint blockade</dc:subject>
          <dc:subject>users among patients</dc:subject>
          <dc:subject>hr range 0</dc:subject>
          <dc:subject>target trial</dc:subject>
          <dc:subject>slc6a4 expression</dc:subject>
          <dc:subject>immune checkpoint</dc:subject>
          <dc:subject>tumor immune</dc:subject>
          <dc:subject>ssri users</dc:subject>
          <dc:subject>among 3</dc:subject>
          <dc:subject>solid tumor</dc:subject>
          <dc:subject>composite immune</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>versus 34</dc:subject>
          <dc:subject>thyroid dysfunction</dc:subject>
          <dc:subject>starting within</dc:subject>
          <dc:subject>ssri use</dc:subject>
          <dc:subject>ssri repurposing</dc:subject>
          <dc:subject>ssri group</dc:subject>
          <dc:subject>solid tumors</dc:subject>
          <dc:subject>serotonin transporter</dc:subject>
          <dc:subject>residual confounding</dc:subject>
          <dc:subject>psychiatric comorbidity</dc:subject>
          <dc:subject>primary outcome</dc:subject>
          <dc:subject>performance status</dc:subject>
          <dc:description>&lt;p&gt;&lt;b&gt;a&lt;/b&gt;, Kaplan–Meier survival curves for SSRI (blue) vs. BZD (orange) cohorts with 95% CIs and number-at-risk table. HR 0.627; 95% CI [0.549, 0.716]; log-rank &lt;i&gt;p&lt;/i&gt; &lt; 0.001. &lt;b&gt;b&lt;/b&gt;, Cumulative mortality at prespecified time points with absolute risk differences. The absolute difference in survival increased from 3.0% at 3 months to 14.9% at 24 months. Panel &lt;i&gt;b&lt;/i&gt; values are Kaplan–Meier estimates, which account for censoring and are therefore higher than the crude proportions reported in the Abstract and &lt;a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1005262#pmed.1005262.t002" target="_blank"&gt;Table 2&lt;/a&gt;. &lt;i&gt;N&lt;/i&gt; = 1,567 propensity score-matched pairs per group.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-29T18:01:32Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pmed.1005262.g003</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Primary_outcome_Overall_survival_p_/34026790</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
